Sridhar Mani

Tyrosine kinase inhibitors: a clinical perspective.

Oxaliplatin: a review of evolving concepts.

Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.

Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.

Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study.

Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.

Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.

Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.

A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma.

The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics.

A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer.

Current approaches to novel therapeutics in pancreatic cancer.

Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase.

Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors.

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.

9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.

The clinical development of new mitotic inhibitors that stabilize the microtubule.

UCN-01 alters phosphorylation of Akt and GSK3beta and induces apoptosis in six independent human neuroblastoma cell lines.

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.

A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.

Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.

A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines.

Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.

Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.

Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents.

Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.

Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.

A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.

Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282.

Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.

Autoantibody cancer biomarker: extracellular protein kinase A.

Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.

Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.

Activated pregnenolone X-receptor is a target for ketoconazole and its analogs.

Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.

Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites.

Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.

The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor.

Rhabdoid tumor growth is inhibited by flavopiridol.

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

Agranulocytosis induced by nonchemotherapy drugs.

The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.

Computational discovery of novel low micromolar human pregnane X receptor antagonists.

Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR).

Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer.

Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism.

A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.

The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies.

Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions.

Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists.

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics.

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.

Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma.

Orphan nuclear receptors as targets for drug development.

Evaluation of computational docking to identify pregnane X receptor agonists in the ToxCast database.

Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.

Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.

Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.

Acetylation of pregnane X receptor protein determines selective function independent of ligand activation.

Post-translational modification of pregnane x receptor.

In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation.

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice.

Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.

Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene.

Sixth International Congress on Shwachman-Diamond syndrome: from patients to genes and back.

Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.

Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis.

Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response.

PXR antagonists and implication in drug metabolism.

Methodologies to decipher the cell secretome.

Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling.

Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR.

Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway.

Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity.

Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010.

Understanding and Modulating Mammalian-Microbial Communication for Improved Human Health.